Hypochondroplasia clinical trials

Explore recruiting hypochondroplasia clinical trials.

Recruiting hypochondroplasia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypochondroplasia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months

Germany, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

Spain, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children with Hypochondroplasia: ACCEL 2/3

Norway, France, Sweden, Portugal, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia

Spain, Germany, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia

France, Spain, Italy, Germany